These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 19426122)

  • 1. Current investigational drugs for major depression.
    Kulkarni SK; Dhir A
    Expert Opin Investig Drugs; 2009 Jun; 18(6):767-88. PubMed ID: 19426122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in the treatment of depression.
    Holtzheimer PE; Nemeroff CB
    NeuroRx; 2006 Jan; 3(1):42-56. PubMed ID: 16490412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experimental medication treatment approaches for depression.
    Ionescu DF; Papakostas GI
    Transl Psychiatry; 2017 Mar; 7(3):e1068. PubMed ID: 28323287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Getting the balance right: Established and emerging therapies for major depressive disorders.
    Perović B; Jovanović M; Miljković B; Vezmar S
    Neuropsychiatr Dis Treat; 2010 Sep; 6():343-64. PubMed ID: 20856599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. sigma-1 receptors in major depression and anxiety.
    Kulkarni SK; Dhir A
    Expert Rev Neurother; 2009 Jul; 9(7):1021-34. PubMed ID: 19589051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigational drugs for treating major depressive disorder.
    Dhir A
    Expert Opin Investig Drugs; 2017 Jan; 26(1):9-24. PubMed ID: 27960559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of Zuranolone for treatment of depression: A systematic review and meta-analysis.
    Fayoud AM; Orebi HA; Elshnoudy IA; Elsebaie MAT; Elewidi MMM; Sabra HK
    Psychopharmacology (Berl); 2024 Jul; 241(7):1299-1317. PubMed ID: 38802705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of Psilocybin Use for Depression among Cancer Patients after Approval in Oregon.
    Bellman V
    Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ROS-Targeted Depression Therapy via BSA-Incubated Ceria Nanoclusters.
    Fu S; Chen H; Yang W; Xia X; Zhao S; Xu X; Ai P; Cai Q; Li X; Wang Y; Zhu J; Zhang B; Zheng JC
    Nano Lett; 2022 Jun; 22(11):4519-4527. PubMed ID: 35583518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, Synthesis, and Functional Evaluation of 1, 5-Disubstituted Tetrazoles as Monoamine Neurotransmitter Reuptake Inhibitors.
    Paudel S; Wang S; Kim E; Kundu D; Min X; Shin CY; Kim KM
    Biomol Ther (Seoul); 2022 Mar; 30(2):191-202. PubMed ID: 34789584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase III Prospective Active and Placebo-Controlled Randomized Trial of Vilazodone in the Treatment of Major Depressive Disorder.
    Sinha S; Chary S; Thakur P; Talluri L; Reddy M; Verma KK; Saha P; Gupta VB; Ramaiah KA; Khanum SZ
    Cureus; 2021 Jul; 13(7):e16689. PubMed ID: 34513348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paroxetine combined with fluorouracil plays a therapeutic role in mouse models of colorectal cancer with depression through inhibiting IL-22 expression to regulate the MAPK signaling pathway.
    Zhang H; Chen M; Liu Y; Dong X; Zhang C; Jiang H; Chen X
    Exp Ther Med; 2020 Dec; 20(6):240. PubMed ID: 33178338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathological ATPergic Signaling in Major Depression and Bipolar Disorder.
    Illes P; Verkhratsky A; Tang Y
    Front Mol Neurosci; 2019; 12():331. PubMed ID: 32076399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-Aminopyrazole as precursor in design and synthesis of fused pyrazoloazines.
    Aggarwal R; Kumar S
    Beilstein J Org Chem; 2018; 14():203-242. PubMed ID: 29441143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of vilazodone for major depressive disorder: evidence from phase III/IV randomized controlled trials.
    Shi L; Wang J; Xu S; Lu Y
    Drug Des Devel Ther; 2016; 10():3899-3907. PubMed ID: 27932864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update.
    Wang SM; Han C; Lee SJ; Jun TY; Patkar AA; Masand PS; Pae CU
    Chonnam Med J; 2016 Sep; 52(3):159-72. PubMed ID: 27689026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vilazodone for the Treatment of Depression: An Update.
    Wang SM; Han C; Lee SJ; Patkar AA; Masand PS; Pae CU
    Chonnam Med J; 2016 May; 52(2):91-100. PubMed ID: 27231672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain Rewarding Stimulation Reduces Extracellular Glutamate Through Glial Modulation in Medial Prefrontal Cortex of Rats.
    Murakami G; Nakamura M; Takita M; Ishida Y; Ueki T; Nakahara D
    Neuropsychopharmacology; 2015 Nov; 40(12):2686-95. PubMed ID: 25924203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-α-Oxyazetidine.
    Han M; Song C; Jeong N; Hahn HG
    ACS Med Chem Lett; 2014 Sep; 5(9):999-1004. PubMed ID: 25221656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigations on agglomeration and haemocompatibility of vitamin E TPGS surface modified berberine chloride nanoparticles.
    Vuddanda PR; Rajamanickam VM; Yaspal M; Singh S
    Biomed Res Int; 2014; 2014():951942. PubMed ID: 25162037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.